The influence of toxicity constraints in models of chemotherapeutic protocol escalation

Mathematical Medicine and Biology

Volumn 28, Issue 4, 2011, Pages 357-384

  Boston, Eleanor A J ^a   Gaffney, Eamonn A ^b  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Age structured modelling; Cell cycle phase specificity; Chemotherapeutic protocol modelling; Drug resistance; Toxicity constraints

Indexed keywords

CELLS; CYTOLOGY; DENSIFICATION; DRUG DOSAGE; SCHEDULING;

AGE STRUCTURED MODEL; CELL CYCLE PHASE; CELL CYCLE PHASE SPECIFICITY; CHEMOTHERAPEUTIC PROTOCOL MODELING; COMPUTATIONAL MODELLING; DENSIFICATIONS; DRUG ADMINISTRATION; DRUG-RESISTANCE; PROTOCOL MODELING; TOXICITY CONSTRAINT;

TOXICITY;

EID: 83455165061     PISSN: 14778599     EISSN: 14778602     Source Type: Journal    
DOI: 10.1093/imammb/dqr004     Document Type: Article

References (75)

1. ABDREEFF, M., GOODRICH, D. W. & PARDEE, A. B. (2000) Cell proliferation, differentiation and apoptosis, Chapter 2. The Holland-Frei Cancer Medicine, 5th edn. (R. C. Bast, D. W. Kufe, R. E. Pollack, R. R. Weischelbaum, J. F. Holland & E. Frei eds). Hamilton, ON: BC Decker Inc., pp. 17-32.
2. ADAM, R. (2006) Current surgical strategies for the treatment of colorectal cancer liver metastases. Eur. J. Cancer Suppl., 2, 21-26.
3. AFENYA, E. K. (2001) Recovery of normal hemopoiesis in disseminated cancer therapy-a model. Math. Biosci., 172, 15-32.
4. AGUR, Z., ARNON, R. & SCHECHTER, B. (1988) Reduction of cytotoxicity to normal tissues by new regimens of cell-cycle phase-specific drugs. Math. Biosci., 92, 1-15.
5. AGUR, Z., ARNON, R. & SCHECHTER, B. (1992) Effect of the dosing interval on myelotoxicity and survival in mice treated by cytarabine. Eur. J. Cancer, 28A, 1085-1090.
6. BARBOLOSI, D. & ILIADIS, A. (2001) Optimizing drug regimens in cancer chemotherapy: a simulation study using a PK-PD model. Comput. Biol. Med., 31, 157-172.
7. BOSTON, E. (2008) Effects of incorporating toxic constraints to predictions of optimal chemotherapy scheduling. Ph.D Thesis, University of Birmingham, UK.
8. BROWDER, T., BUTTERFIELD, C. E., KRALING, B. M., SHI, B., MARSHALL, B., OREILLY, M. & FOLKMAN, J. (2000) Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res., 60, 1878-1886.
9. CHIORINO, G., METZ, J. A. J., TOMASONI, D. & UBEZIO, P. (2001) Desynchronization rate in cell populations: mathematical modeling and experimental data. J. Theor. Biol., 208, 185-199.
10. CITRON, M., BERRY, D., CIRRINCIONE, C., CARPENTER, J., HUDIS, C., GRADISHAR, W., DAVIDSON, N., INGLE, J., MARTINO S., LIVINGSTON, R., WINER, E., MUSS, H. & NORTON, L. (2002) Superiority of dose-dense (DD) over conventional scheduling (CS) and equivalence of sequential (SC) vs. combination adjuvant chemotherapy (CC) for node-positive breast cancer (CALGB 9741, INT C9741). Breast Cancer Research and Treatment 76, S32-S32.
11. CITRON, M. L., BERRY, D. A., CIRRINCIONE, C., HUDIS, C., WINER, E. P., GRADISHAR, W. J., DAVIDSON, N. E., MARTINO, S., LIVINGSTON, R., INGLE, J. N., PEREZ, E. A., CARPENTER, J., HURD, D., HOLLAND, J. F., SMITH, B. L., SARTOR, C. I., LEUNG, E. H., ABRAMS, J., SCHILSKY, R. L., MUSS, H. B. & NORTON, L. (2003) Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of intergroup trial C9741/cancer and leukemia group b trial 9741. J. Clin. Oncol., 21, 1431-1439.
12. COHEN, A. D. & KEMENY, N. (2003) An update on hepatic arterial infusion chemotherapy for colorectal cancer. Oncologist, 8, 553-556.
13. COJOCARU, L. & AGUR, Z. (1992) Theoretical analysis of interval drug dosing for cell-cycle-phase-specific drugs. Math. Biosci., 109, 85-97.
14. CONLON, I. & RAFF, M. (2003) Differences in the way a mammalian cell and yeast cells coordinate cell growth and cell-cycle progression. J. Biol., 2, 7.
15. COOPER, S. (2000) The continuum model and the G1-control of the mammalian cell cycle. Progress in Cell Cycle Research (M. Meijer, A. Jezequel & B. Ducommun, eds.), vol. 4, New York: Plenum Press, pp. 27-39.
16. COSTA, M. I. S., BOLDRINI, J. L. & BASSANEZI, R. C. (1995) Chemotherapeutic treatments involving drug resistance and level of normal cells as a criterion of toxicity. Math. Biosci., 125, 211-228.
17. COURT, F. G., WEMYSS-HOLDEN, S. A., DENNISON, A. R. & MADDERN, G. J. (2002) The mystery of liver regeneration. Br. J. Surg., 89, 1089-1095.
18. DEPLACIDO, S., PERRONE, F., CARLOMAGNO, C., MORABITO, A., PAGLIARULO, C., LAURIA, R., MARINELLI, A., DELAURENTIIS, M., VARRIALE, E., PETRELLA, G., GALLO, C. & BIANCO, A. R. (1995) CMF vs alternating CMF/EV in the adjuvant treatment of operable breast cancer. a single centre randomised clinical trial (Naples GUN-3 study). Br. J. Cancer, 71, 1283-1287.
19. DIBROV, B. (1998) Resonance effect in self-renewing tissues. J. Theor. Biol., 192, 15-33.
20. ENSMINGER, W., ROSOWSKY, A., RASO, V., LEVIN, D., GLODE, M., CONE, S., STEELE, G. & FREI, E. (1978) A clinical-pharmacological evaluation of hepatic arterial infusions of 5 fluoro-2/deoxuridine and 5-fluorouracil. Ann. Oncol., 38, 3784-3792.
21. FALLIK, D., YCHOU, M., JACOB, J., COLIN, P., SEITZ, J. F., BAULIEUX, J., ADENIS, A. & DOUILLARD, J. (2003) Hepatic arterial infusion using pirarubicin combined with systemic chemotherapy: a phase II study in patients with nonresectable liver metastases from colorectal cancer. Ann. Oncol., 14, 856-863.
22. FREI, E. & ANTMAN, K. (2000) Principles of dose, schedule and combination chemotherapy, Chapter 40. The Holland-Frei Cancer Medicine, 5th edn. BC Decker Inc., pp. 556-568.
23. GAFFNEY, E. A. (2004) The application of mathematical modelling to aspects of adjuvant chemotherapy scheduling. J. Math. Biol., 48, 375-422.
24. GAFFNEY, E. A. (2005) The mathematical modelling of adjuvant chemotherapy scheduling: incorporating the effects of protocol rest phases and pharmacokinetics. Bull. Math. Biol., 67, 563-611.
25. GOLDIE, J. H. & COLDMAN, A. J. (1979) A mathematical model for relating the drug sensitivity of tumours to their spontaneous mutation rate. Cancer Treat. Rep., 63, 1727-1731.
26. GOLDIE, J. H. & COLDMAN, A. J. (1983a) A model for the resistance of tumor cells to cancer chemotherapy. Math. Biosci., 65, 291-307.
27. GOLDIE, J. H. & COLDMAN, A. J. (1983b) Quantitative model for multiple levels of drug resistance in clinical tumours. Cancer Treat. Rep., 67, 923-931.
28. GOLDIE, J. H. & COLDMAN, A. J. (1986) Application of theoretical models to chemotherapy protocol design. Cancer Treat. Rep., 70, 127-131.
29. GOLDIE, J. H. & COLDMAN, A. J. (1998) Drug Resistance in Cancer: Mechanisms and Models. Cambridge: Cambridge University Press.
30. GOLDIE, J. H., COLDMAN, A. J. & GUDAUSKAS, G. A. (1982) Rationale for the use of alternating non-cross resistant chemotherapy. Cancer Treat. Rep., 66, 439-449.
31. HAHNFELDT, P., FOLKMANY, J. & HLATKY, L. (2003) Minimizing long-term tumor burden: the logic for metronomic chemotherapeutic dosing and its antiangiogenic basis. J. Theor. Biol., 220, 545-554.
32. HAINES, I. E. (2008) Dose selection in phase I studies: why we should always go for the most effective (correspondence). J. Clin. Oncol., 26, 3650-2652.
33. INOMATA, A., HORII, I. & SUZUKI, K. (2002) 5-Fluorouracil-induced intestinal toxicity: what determines the severity of damage to murine intestinal crypt epithelia? Toxicol. Lett., 133, 231-240.
34. JAFFREZOU, J. P., CHEN, G., DURAN, G. E., KUHL, J. S. & SIKIC, B. (1994) Mutation rates and mechanisms of resistance to etoposide determined from fluctuation analysis. J. Natl. Cancer Inst., 86, 1152-1158.
35. KEMENY, N. & FATA, F. (2001) Hepatic-arterial chemotherapy. Lancet Oncol., 2, 418-428.
36. KEMENY, N., HUANG, Y., COHEN, A., SHI, W., CONTI, J., BRENNAN, M., BERTINO, J., TURNBULL, A., SULLIVAN, D., STOCKMAN, J., BLUMGART, L. & FONG, Y. (1999) Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer. N. Engl. J. Med., 341, 2039-2048.
37. KOLINSKY, K., ZHANG, Y., DUGAN, U., HEIMBROOK, D., PACKMAN, K. & HIGGINS, B. (2009) Novel regimens of capecitabine alone and combined with irinotecan and bevacizumab in colorectal cancer xenografts. Anticancer Res., 29, 91-98.
38. LAW, L. W. (1952) Origin of the resistance of leukaemic cells to folic acid antagonists. Nature, 169, 628-629.
39. LESAGE, G., GLASER, S. S., GUBBA, S., ROBERTSON, W. E., PHINIZY, J., LASATER, J., RODGERS, R. D. & ALPINI, G. (1996) Regrowth of the rat biliary tree after 70% partial hepatectomy is coupled to increased secretin-induced ductal secretion. Gastroenterology, 111, 1633-1644.
40. LOEB, L. A., LOEB, K. R. & ANDERSON, J. P. (2003) Multiple mutations and cancer. Proc. Natl. Acad. Sci. USA., 100, 776-781.
41. LURIA, S. E. & DELBRÜCK, M. (1943) Mutations of bacteria from virus sensitivity to virus resistance. Genetics, 28, 491-511.
42. MARKMAN, M. (1993) Optimal versus maximally tolerated dose in cancer chemotherapy treatment. J. Cancer Res. Clin. Oncol., 119, 576-577.
43. MARZIONI, M., GLASER, S., FRANCIS, H., MARUCCI, L., BENEDETTI, A., ALVARO, D., TAFFETANI, S., UENO, Y., ROSKAMS, T., PHINIZY, J. L., VENTER, J., FAVA, G., LESAGE, G. D. & ALPINI, G. (2005) Autocrine/paracrine regulation of the growth of the biliary tree by the neuroendocrine hormone serotonin. Gastroenterology, 128, 121-137.
44. MATVEEV, A. S. & SAVKIN, A. V. (2005) Influence of tumours on normal cells and optimal chemotherapy regimens: the case of several drugs and toxicity constraints. Math. Med. Biol., 22, 143-162.
45. MIDGLEY, R. S. J. & KERR, D. J. (1999) Seminar in colorectal cancer. Lancet, 353, 391-399.
46. MIDGLEY, R. S. J. & KERR, D. J. (2000) ABC of colorectal cancer: adjuvant therapy. BMJ, 321, 1208-1211.
47. MORTON, K. & MAYERS, D. (2005) Numerical Solution of Partial Differential Equations: An Introduction. Cambridge: Cambridge University Press.
48. MUSGROVE, E. A., LEE, C. S. L., BUCKLEY, M. F. & SUTHERLAND, R. L. (1994) Cyclin D1 induction in breast cancer cells shortens G1 and is sufficient for cells arrested in G1 to complete the cell cycle. Proc. Natl. Acad. Sci. USA., 91, 8022-8026.
49. NICUM, S., MIDGLEY, R. & KERR, D. J. (2000) Chemotherapy for colorectal cancer. J. R. Soc. Med., 93, 416-419.
50. NORTON, L. (1998a) A Gompertzian model of human breast cancer growth. Cancer Res., 48, 7067-7071.
51. NORTON, L. (1998b) Evolving concepts in the systemic drug therapy of breast cancer. Semin. Oncol., 24, S10-3-S10-10.
52. NORTON, L. (2001) Theoretical concepts and the emerging role of taxanes in adjuvant therapy. Oncologist, 6, 30-35.
53. NORTON, L. (2005) Conceptual and practical implications of breast tissue geometry: toward a more effective, less toxic therapy. Oncologist, 10, 370-381.
54. NORTON, L. (2008) The concept of mathematically optimised dose-scheduling as applied to the adjuvant chemotherapy of primary breast cancer: theory and recent results. Eur. J. Cancer Suppl., 6, 10-16.
55. NORTON, L. & SIMON, R. (1977) Tumor size, sensitivity to therapy, and design of treatment schedules. Cancer Treat. Rep., 61, 1307-1317.
56. NORTON, L. & SIMON, R. (1986) The Norton-Simon hypothesis revisited. Cancer Treat. Rep., 70, 163-169.
57. OKAMOTO, S., SAKAI, M., UCHIDA, J. & SAITO, H. (1996) 5-Fluorouracil induces apoptotic cell death with G2 phase arrest in human breast cancer grafted in nude mice. Anticancer Res., 16, 2699-2704.
58. PALMES, D. & SPIEGEL, H. (2004) Animal models of liver regeneration. Biomaterials, 25, 1601-1611.
59. PANETTA, J. C. & ADAM, J. (1995) A mathematical model of cycle-specific chemotherapy. Math. Comput. Modelling, 22, 67-82.
60. PICCART, M. J., BIGANZOLI, L. & DI LEO, A. (2000) The impact of chemotherapy dose density and dose intensity on breast cancer outcome: what have we learned? Eur. J. Cancer, 36, S4-S10.
61. REW, D. A. & WILSON, G. D. (2000) Cell production rates in human tissue and tumours and their significance. Part II: clinical data. Eur. J. Surg. Oncol., 26, 405-417.
62. SIEBER, M., TESCH, H., PFISTNER, B., RUEFFER, U., LATHAN, B., BROSTEANU, O., PAULUS, U., KOCH, T., PFREUNDSCHUH, M., LOEFFLER, M., ENGERT, A., JOSTING, A., WOLF, J., HASENCLEVER, D., FRANKLIN, J., et al. (2002) Rapidly alternating COPP/ABV/IMEP is not superior to conventional alternating COPP/ABVD in combination with extended-field radiotherapy in intermediate-stage hodgkin's lymphoma: final results of the German Hodgkin's Lymphoma study Group Trial HD5. J. Clin. Oncol., 20, 476-484.
63. SIMON, R. & NORTON, L. (2006) The Norton-Simon hypothesis: designing more effective and less toxic chemotherapeutic regimens. Nat. Clin. Pract. Oncol., 3, 406-407.
64. SIODLAK, M. Z., STELL, P. M., WILSON, J. A., GREEN, R. S., ALLISON, D., ADLER, M. & SQUADRELLISARACENO, M. (1990) Alternating cisplatinum and VAC ineffective in end stage squamous cell carcinoma of the head and neck. J. Laryngol. Otol., 104, 631-633.
65. SKIPPER, H. E. (1965) The effects of chemotherapy on the kinetics of leukaemic cell behaviour. Cancer Res., 25, 1544-1550.
66. SKITZKI, J. & CHANG, A. E. (2002) Hepatic artery chemotherapy for colorectal liver metastases: technical considerations and review of clinical trials. Surg. Oncol., 11, 123-135.
67. SUMMERS, W. P. & HANDSHUMACHER, R. (1973) The rate of mutation of l5178y asparagine-dependent mouse leukemia cells to asparagine independence and its biological consequences. Cancer Res., 33, 1775-1779.
68. TAKAHASHI, T., BHIDE, P. G., GOTO, T., MIYAMA, S. & CAVINESS, V. S. (1999) Proliferative behavior of the murine cerebral wall in tissue culture: cell cycle kinetics and checkpoints. Exper. Neurol., 156, 407-417.
69. TEBBUTT, N. C., CATTELL, E., MIDGLEY, R., CUNNINGHAM, D. & KERR, D. (2002) Systemic treatment of colorectal cancer. Eur. J. Cancer, 38, 1000-1015.
70. TRAINA, T. A., THEODOULOU, M., FEIGIN, K., PATIL, S., TAN, K. L., EDWARDS, C., DUGAN, U., NORTON, L. & HUDIS, C. (2008) Phase I study of a novel capecitabine schedule based on the Norton-Simon mathematical model in patients with metastatic breast cancer. J. Clin. Oncol., 26, 1797-1802.
71. UBEZIO, P., TAGLIABUE, G., SCHECHTER, B. & AGUR, Z. (1994) Increasing 1-beta-d-arabinofuranosylcytosine efficacy by scheduled dosing intervals based on direct measurements of bone-marrow cell-kinetics. Cancer Res., 54, 6446-6451.
72. WEBB, G. (1990) Resonance phenomena in cell population chemotherapy models. Rocky Mountain J. Math., 20, 1195-1216.
73. WHELDON, T. E. (1988) Mathematical Models in Cancer Research. Bristol: Adam Hilger.
74. WOLFE, S. L. (1995) Introduction to Cell and Molecular Biology. California: Wadsworth.
75. ZETTERBERG, A., LARSSON, O. & WIMAN, K. G. (1995) What is the restriction point? Curr. Opin. Cell Biol., 7, 835-842.